Recruiting
PHASE4
INTERVENTIONAL
NCT06635057
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The main purpose of the study is to investigate whether tirzepatide can be effectively started before Ramadan and used per label in participants with Type 2 Diabetes during the fasting month.
Interventions
Name:
Tirzepatide
Type:
DRUG
Description:
Administered SC
Primary Outcomes
Measure:
Change from Baseline in Hemoglobin A1c (HbA1c)
TimeFrame:
Baseline (20 to 8 weeks Before Ramadan), Week 4-8 from Start of Ramadan (SoR)
Description:
Trial Information
NCT ID
NCT06635057
Status
Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE4
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025